Triple-action weekly weight-loss drug reduces sleep apnea in two late-stage trials
A triple-action weekly weight-loss drug significantly reduces obstructive sleep apnea severity in two late-stage clinical trials.
268 trends tracked about this subject — the full history, oldest to newest below.
A triple-action weekly weight-loss drug significantly reduces obstructive sleep apnea severity in two late-stage clinical trials.
Recent reporting examines the available evidence regarding weight-loss drugs and bone health.
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
FDA moves to curb bulk compounding of GLP‑1 weight‑loss drugs as legal action hits telehealth firm HIMS
8 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
19 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Recent studies link popular GLP-1 weight-loss drugs to unexpected dermatological side effects like nail detachment and hair loss.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Recent coverage links GLP-1 medications like Ozempic and Wegovy to legal action involving vision loss alongside contrasting studies.
Walmart expands employee health benefits to include free GLP-1 drugs and hundreds of medications.
A growing wave of coverage examines newly reported links between popular GLP-1 medications and rare instances of severe vision loss.
Unapproved weight loss drug retatrutide faces a booming black market linked to multiple reported deaths and severe side effects.
Obesity drugs face a major pivot as clinical trials investigate their potential to treat addiction, depression, and criminal behavior.
1 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Recent reporting examines whether GLP-1 weight-loss medications could help women conceive and boost fertility outcomes.
Recent coverage examines what happens when individuals stop taking GLP-1 weight loss and diabetes medications.
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Early research indicates GLP-1 weight-loss drugs may slow biological aging by up to four years, according to recent coverage.
Federal regulators face mounting scrutiny as unapproved weight-loss drugs and new safety warnings enter public focus.
Recent scientific findings point to potential methods for limiting weight regain after patients stop taking GLP-1 medications.
Recent studies indicate that popular GLP-1 weight-loss medications like Ozempic and Mounjaro may also slow biological aging.
Recent coverage examines the rising use of GLP-1 medications among children, highlighting strong weight loss alongside nutritional and data gaps.
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
15 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Ongoing legal actions and international reports highlight severe risks linked to weight-loss drugs.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Recent coverage examines the phenomenon of 'Ozempic babies' and the broader relationship between GLP-1 drugs and women's health.
2 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
PepsiCo slashes its profit outlook as the North American revival stalls, sparking investor concern over cost pressures and a new GLP‑1 health trend.
10 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Global health guidance diverges on childhood obesity treatments as the WHO recommends lifestyle changes over GLP-1 drugs for young children.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Recent findings indicate that GLP-1 weight-loss drugs can potentially lead to nail loss, expanding known side effects.
Recent scientific findings reveal a molecular clue regarding why individuals often regain weight after dieting or stopping medications.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Recent studies link popular GLP-1 weight-loss drugs to surprising physical side effects including hair loss and nail troubles.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
1 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Recent studies link weight-loss medications like Ozempic and Wegovy to unexpected hair and nail side effects.
A Massachusetts man's lawsuit alleging permanent blindness from Ozempic highlights growing legal and medical concerns over GLP-1 weight loss drugs.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Real-world study data reveals patients switching from obesity injections to Novo Nordisk's oral Wegovy pill continue to lose weight.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Recent coverage highlights a striking statistic regarding US metabolic health alongside fitness advice for GLP-1 users.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
1 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
GLP-1 medications are shifting from clinical obesity treatments for patients to lifestyle products for customers, amid a surge in oral pill options.
Health experts are highlighting specific strength training strategies for individuals utilizing GLP-1 weight-loss medications to manage physical health.